Radium-223 behandling af knoglemetastaser ved kastrationsrefraktær prostatacancer

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Radium-223 behandling af knoglemetastaser ved kastrationsrefraktær prostatacancer. / Mortensen, Jann; Højgaard, Liselotte.

I: Ugeskrift for Laeger, Bind 176, Nr. 30, 21.07.2014, s. 1399-1402.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Mortensen, J & Højgaard, L 2014, 'Radium-223 behandling af knoglemetastaser ved kastrationsrefraktær prostatacancer', Ugeskrift for Laeger, bind 176, nr. 30, s. 1399-1402.

APA

Mortensen, J., & Højgaard, L. (2014). Radium-223 behandling af knoglemetastaser ved kastrationsrefraktær prostatacancer. Ugeskrift for Laeger, 176(30), 1399-1402.

Vancouver

Mortensen J, Højgaard L. Radium-223 behandling af knoglemetastaser ved kastrationsrefraktær prostatacancer. Ugeskrift for Laeger. 2014 jul. 21;176(30):1399-1402.

Author

Mortensen, Jann ; Højgaard, Liselotte. / Radium-223 behandling af knoglemetastaser ved kastrationsrefraktær prostatacancer. I: Ugeskrift for Laeger. 2014 ; Bind 176, Nr. 30. s. 1399-1402.

Bibtex

@article{b17ff97d15fb4d83810b89119d7eacef,
title = "Radium-223 behandling af knoglemetastaser ved kastrationsrefrakt{\ae}r prostatacancer",
abstract = "The alpha emitter Radium-223 ((22)3Ra-Cl2) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone refractory prostate cancer. More than 1,000 patients have been included in clinical phase I-III tests showing significant reduction in alkaline phosphatase- and PSA level and prolonged survival. Adverse events are usually mild to moderate and comprise gastrointestinal and myelotoxic symp-toms. Intravenously administered (22)3Ra-Cl2 (half-life 11.4 days) will likely be given every four weeks for six treatments to out-patients.",
author = "Jann Mortensen and Liselotte H{\o}jgaard",
year = "2014",
month = jul,
day = "21",
language = "Dansk",
volume = "176",
pages = "1399--1402",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "30",

}

RIS

TY - JOUR

T1 - Radium-223 behandling af knoglemetastaser ved kastrationsrefraktær prostatacancer

AU - Mortensen, Jann

AU - Højgaard, Liselotte

PY - 2014/7/21

Y1 - 2014/7/21

N2 - The alpha emitter Radium-223 ((22)3Ra-Cl2) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone refractory prostate cancer. More than 1,000 patients have been included in clinical phase I-III tests showing significant reduction in alkaline phosphatase- and PSA level and prolonged survival. Adverse events are usually mild to moderate and comprise gastrointestinal and myelotoxic symp-toms. Intravenously administered (22)3Ra-Cl2 (half-life 11.4 days) will likely be given every four weeks for six treatments to out-patients.

AB - The alpha emitter Radium-223 ((22)3Ra-Cl2) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone refractory prostate cancer. More than 1,000 patients have been included in clinical phase I-III tests showing significant reduction in alkaline phosphatase- and PSA level and prolonged survival. Adverse events are usually mild to moderate and comprise gastrointestinal and myelotoxic symp-toms. Intravenously administered (22)3Ra-Cl2 (half-life 11.4 days) will likely be given every four weeks for six treatments to out-patients.

M3 - Tidsskriftartikel

C2 - 25292232

VL - 176

SP - 1399

EP - 1402

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 30

ER -

ID: 137378962